Exploring Dato-DXd Combinations as First-Line Therapy for Advanced NSCLC

Author(s):

Julia Rotow, MD, explores the rationale, study design, and primary endpoints of the AVANZAR trial, which investigated the combination of datopotamab deruxtecan (Dato-DXd), durvalumab, and carboplatin as a first-line treatment for patients with advanced non-small cell lung cancer lacking actionable mutations, and discusses the patient population most likely to benefit from this drug combination.

EP: 1.Treatment Strategies for NSCLC with Non-Actionable Mutations

EP: 2.Role of Antibody-Drug Conjugates in NSCLC Treatment: Insights from EVOKE-02

EP: 3.Exploring the TROPION-Lung04 Study

Now Viewing

EP: 4.Exploring Dato-DXd Combinations as First-Line Therapy for Advanced NSCLC

EP: 5.Navigating Between ADCs in NSCLC

EP: 6.Advancing Treatment for EGFR-Mutant Advanced NSCLC: Lessons from FLAURA2

EP: 7.Osimertinib Monotherapy vs. Combination Therapy: Patient Selection in EGFR-Mutant Advanced NSCLC

EP: 8.MARIPOSA Study Insights

EP: 9.Optimizing Therapy Selection in EGFR Mutant NSCLC

EP: 10.ASCO 2024 Updates: Novel Approaches in NSCLC Therapy

EP: 11.Overview of TROP2 & Potential Role of TROP2-Directed ADCs in NSCLC

EP: 12.Key Takeaways from TROPION Trials: Implications for NSCLC Treatment Landscape

EP: 13.Targeting of HER3: Insights from HERTHENA-Lung01

EP: 14.Challenges and Learnings from EVOKE-01

EP: 15.Key ADC Studies at ASCO 2024

EP: 16.Mitigating Toxicities of Dato-DXd, Sacituzumab Govitecan, and HER3-DXd

EP: 17.Patient Selection and Sequencing of NSCLC ADCs

Please discuss the rationale, study design, and key endpoints for the AVANZAR (Aggarwal et al. WCLC 2023) trial evaluating Dato-DXd + durvalumab and carboplatin for 1L treatment of patients with advanced NSCLC without actionable mutations.
1. What is the rationale for this treatment approach?
2. What data do you anticipate and how may findings impact the current/future treatment landscape?
3. In which patients would this treatment strategy most appropriate/beneficial?